Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Background Several clinical trials have reported inconsistent findings for the effect of fibrates on cardiovascular risk. We undertook a systematic review and meta-analysis to investigate the effects of fibrates on major clinical outcomes. Methods We systematically searched Medline, Embase, and the Cochrane Library for trials published between 1950 and March, 2010. We included prospective randomised controlled trials assessing the effects of fibrates on cardiovascular outcomes compared with placebo. Summary estimates of relative risk (RR) reductions were calculated with a random effects model. Outcomes analysed were major cardiovascular events, coronary events, stroke, heart failure, coronary revascularisation, all-cause mortality, cardiovascular death, non-vascular death, sudden death, new onset albuminuria, and drug-related adverse events. Findings We identified 18 trials providing data for 45 058 participants, including 2870 major cardiovascular events, 4552 coronary events, and 3880 deaths. Fibrate therapy produced a 10% RR reduction (95% CI 0-18) for major cardiovascular events (p=0.048) and a 13% RR reduction (7-19) for coronary events (p Interpretation Fibrates can reduce the risk of major cardiovascular events predominantly by prevention of coronary events, and might have a role in individuals at high risk of cardiovascular events and in those with combined dyslipidaemia. Funding National Health and Medical Research Council of Australia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Evidence supporting the prescription of fibrates for cardiovascular prevention remains debated.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [95]
In the citing paper
“A meta-analysis pooling outcomes from these trials found that fibrates significantly reduce the risk of MACE by −10% (95% CI − 0 to − 18, p = 0.048) [94, 95].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [95]
In the citing paper
“The same analysis also finds that fibrates reduce the incidence of coronary events, but not death.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [95]
In the citing paper
“Post hoc subgroup analyses of all of these trials show that the use of fibrates in patients with moderate hypertriglyceridemia results in a decrease in composite cardiovascular events, but not a decrease in mortality (170 -172).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [171]
In the citing paper
“However, these studies also indicate that treatment of patients with triglycerides below 200 mg/dl does not confer benefit.”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [171]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Mortality by cause for eight regions of the world: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07493-4 · Cited by 4,043
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
A Nonparametric “Trim and Fill” Method of Accounting for Publication Bias in Meta-Analysis
Duval, S., & Tweedie, R. (2000) · Journal of the American Statistical Association · doi:10.1080/01621459.2000.10473905 · Cited by 2,955
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
Clofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Hokanson, J. E., & Austin, M. A. (1996) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199604000-00014 · Cited by 1,706
Manninen, V, Tenkanen, L., Koskinen, P., Huttunen, J. K., Mänttäri, M., Heinonen, O. P., & Frick, M. H. (1992) · Circulation · doi:10.1161/01.cir.85.1.37 · Cited by 1,329
Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials
LaRosa, J. C., He, J., & Vupputuri, S. (1999) · JAMA · doi:10.1001/jama.282.24.2340 · Cited by 1,246
Keech, A., Mitchell, P., Summanen, P., O'Day, J., Davis, T., Moffitt, M., Taskinen, M.-R., Simes, R., Tse, D., Williamson, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61607-9 · Cited by 1,109
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
Graham, D. J. (2004) · JAMA · doi:10.1001/jama.292.21.2585 · Cited by 875
Scott, R., O'Brien, R., Fulcher, G., Pardy, C., d'Emden, M., Tse, D., Taskinen, M.-R., Ehnholm, C., Keech, A., & on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-1543 · Cited by 551
Lipoproteins, Cardiovascular Disease, and Death: The Framingham Study
Gordon, T. (1981) · Archives of Internal Medicine · doi:10.1001/archinte.1981.00340090024008 · Cited by 526
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds
Birjmohun, R. S., Hutten, B. A., Kastelein, J. J. P., & Stroes, E. S. G. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.031 · Cited by 429
Barbier, O., Torra, I. P., Duguay, Y., Blanquart, C., Fruchart, J.-C., Glineur, C., & Staels, B. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000015598.86369.04 · Cited by 416
Frick, M. H., Syvänne, M., Nieminen, M. S., Kauma, H., Majahalme, S., Virtanen, V., Kesäniemi, Y. A., Pasternack, A., & Taskinen, M.-R. (1997) · Circulation · doi:10.1161/01.cir.96.7.2137 · Cited by 388
A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate.
Miettinen, M., Turpeinen, O., & Karvonen, M. J. (1979) · Heart · doi:10.1136/hrt.42.3.370 · Cited by 360
Manninen, V., Tenkanen, L., Koskinen, P., Huttunen, J. K., Mänttäri, M., Op, H., & Frick, H. M. (1992) · Circulation · Cited by 360
Marx, N., Kehrle, B., Kohlhammer, K., Grüb, M., Koenig, W., Hombach, V., Libby, P., & Plutzky, J. (2002) · Circulation Research · doi:10.1161/01.res.0000014225.20727.8f · Cited by 331
Elkeles, R. S., Diamond, J. R., Poulter, C., Dhanjil, S., Nicolaides, A. N., Mahmood, S., Richmond, W., Mather, H., Sharp, P., Feher, M. D., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.641 · Cited by 271
Developing a database of published reports of randomised clinical trials in pain research 1
Jadad, A. R., Carroll, D., Moore, A., & McQuay, H. (1996) · Pain · doi:10.1016/0304-3959(96)03033-3 · Cited by 271
Ansquer, J.-C., Foucher, C., Rattier, S., Taskinen, M.-R., & Steiner, G. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.11.004 · Cited by 264
Ischaemic Heart Disease: A Secondary Prevention Trial Using Clofibrate
Research Committee of the Scottish Society of Physicians (1971) · BMJ · doi:10.1136/bmj.4.5790.775 · Cited by 242
Lindvall, C., & Lask, B. (2011) · Eating Disorders and the Brain · doi:10.1002/9781119998402.ch10 · Cited by 218
Bezafibrate in men with lower extremity arterial disease: randomised controlled trial
Meade, T., Zuhrie, R., Cook, C., & Cooper, J. (2002) · BMJ · doi:10.1136/bmj.325.7373.1139 · Cited by 208
Barnes, B. O. (1972) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1972.03200210062029 · Cited by 177
Diabetes Intervention Study: Multi-Intervention Trial in Newly Diagnosed NIDDM
Hanefeld, M., Fischer, S., Schmechel, H., Rothe, G., Schulze, J., Dude, H., Schwanebeck, U., & Julius, U. (1991) · Diabetes Care · doi:10.2337/diacare.14.4.308 · Cited by 166
Letter: Cross-immunity to influenza B virus strains.
Silva, L. M. D., Mortimer, P. P., & Casemore, D. P. (1974) · BMJ · doi:10.1136/bmj.4.5947.767-c · Cited by 134
Risk of adverse events with fibrates*
Alsheikh-Ali, A. A. A., Kuvin, J. T., & Karas, R. H. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.06.033 · Cited by 125
Harris, P. G. (1968) · BMJ · doi:10.1136/bmj.4.5633.775-b · Cited by 121
Ruan, X. Z., Moorhead, J. F., Fernando, R., Wheeler, D. C., Powis, S. H., & Varghese, Z. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000050414.52908.da · Cited by 109
Controlled trial of clofibrate in cerebral vascular disease.
Acheson, J., & Hutchinson, E. (1972) · Atherosclerosis · doi:10.1016/0021-9150(72)90067-6 · Cited by 78
High-density lipoproteins as therapeutic targets
Nicholls, S. J., Rye, K.-A., & Barter, P. J. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000169356.58513.25 · Cited by 42
Self-citationFreyberger, H., Schifferdecker, E., & Schatz, H. (1994) · PubMed · Cited by 27
Emmerich, K.-H., Poritis, N., Stelmane, I., Klindzane, M., Erbler, H., Goldsteine, J., & Görtelmeyer, R. (2009) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/s-0028-1109516 · Cited by 19
Improving outcomes through statin therapy ? a review of ongoing trials
Packard, C. J. (2004) · European Heart Journal Supplements · doi:10.1016/j.ehjsup.2004.01.007 · Cited by 10
Nilsson, J. Å., Ericsson, C.-G., Hamsten, A., Grip, L., Svane, B., & Fairé, U. D. (1997) · Fibrinolysis and Proteolysis · doi:10.1016/s0268-9499(97)80044-6 · Cited by 4
Research works printed but not linked: 1
- Drury, 2008, Reduced renal function (eGFR) and albuminuria in type 2 diabetes independently predict cardiovascular (CVD) events and mortality even in a low risk cohort: the FIELD Study, Circulation, 118, S1088
Cited by
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Self-citationProgress and challenges in translating the biology of atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2011) · Nature · doi:10.1038/nature10146 · Cited by 4,010
“Fibrates effectively decrease triglyceride levels, but trials of these drugs have proven disappointing in reducing clinical events, and have not shown reductions in mortality rate”
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Metadata
- Authors
- Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V.
- Affiliations
- The University of Sydney (AU)
- Cleveland Clinic (US)
- University Medical Center Utrecht (NL)
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2010-05
- Volume
- 375
- Issue
- 9729
- Pages
- 1875-1884
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2096210401
- Semantic Scholar
- 8c363e037861d02ba1dc0122948bf0746b93ee28
- Cited by
- 927
- References
- 49
- Citations by year
- 2026: 17 · 2025: 29 · 2024: 37 · 2023: 52 · 2022: 54 · 2021: 57 · 2020: 48 · 2019: 42 · 2018: 49 · 2017: 58 · 2016: 66 · 2015: 66 · 2014: 79 · 2013: 77 · 2012: 83
- FWCI
- 13.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Servier
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- fibrates, cardiovascular risk reduction, major cardiovascular events, coronary events, stroke, all-cause mortality, cardiovascular mortality, sudden death, albuminuria, drug-related adverse events, serum creatinine, hypertriglyceridemia, lipid-lowering therapy, statins, triglycerides, HDL cholesterol, LDL cholesterol, triglyceride-rich lipoproteins, coronary revascularization
- MeSH terms
- Hypolipidemic Agents, Cardiovascular Diseases, Clofibric Acid, Humans, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.